Literature DB >> 11153635

High-frequency oscillatory ventilation in pediatric respiratory failure: a multicenter experience.

J H Arnold1, N G Anas, P Luckett, I M Cheifetz, G Reyes, C J Newth, K C Kocis, S M Heidemann, J H Hanson, T V Brogan, D J Bohn.   

Abstract

OBJECTIVE: The use of high-frequency oscillatory ventilation (HFOV) has increased dramatically in the management of respiratory failure in pediatric patients. We surveyed ten pediatric centers that frequently use high-frequency oscillation to describe current clinical practice and to examine factors related to improved outcomes.
DESIGN: Retrospective, observational questionnaire study.
SETTING: Ten tertiary care pediatric intensive care units. PATIENTS: Two hundred ninety patients managed with HFOV between January 1997 and June 1998.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Patients were classified according to presence or absence of preexisting lung disease, symptomatic respiratory syncytial virus infection, or presence of cyanotic heart disease or residual right-to-left intracardiac shunt. In addition, patients for whom HFOV acutely failed were analyzed separately. Those patients with preexisting lung disease were significantly smaller, had a significantly higher incidence of pulmonary infection as the triggering etiology, and had a significantly greater duration of conventional ventilation before institution of HFOV compared with patients without preexisting lung disease. Stepwise logistic regression was used to predict mortality and the occurrence of chronic lung disease in survivors. In patients without preexisting lung disease, the model predicted a 70% probability of death when the oxygenation index (OI) after 24 hrs was 28 in the immunocompromised patients and 64 in the patients without immunocompromise. In the immunocompromised patients, the model predicted a 90% probability of death when the OI after 24 hrs was 58. In survivors without preexisting lung disease, the model predicted a 70% probability of developing chronic lung disease when the OI at 24 hrs was 31 in the patients with sepsis syndrome and 50 in the patients without sepsis syndrome. In the patients with sepsis syndrome, the model predicted a 90% probability of developing chronic lung disease when the OI at 24 hrs was 45.
CONCLUSIONS: Given the number of centers involved and the size of the database, we feel that our results broadly reflect current practice in the use of HFOV in pediatric patients. These results may help in deciding which patients are most likely to benefit from aggressive intervention by using extracorporeal techniques and may help identify high-risk populations appropriate for prospective study of innovative modes of supporting gas exchange (e.g., partial liquid breathing or intratracheal pulmonary ventilation).

Entities:  

Mesh:

Year:  2000        PMID: 11153635     DOI: 10.1097/00003246-200012000-00031

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  27 in total

Review 1.  The design of future pediatric mechanical ventilation trials for acute lung injury.

Authors:  Robinder G Khemani; Christopher J L Newth
Journal:  Am J Respir Crit Care Med       Date:  2010-08-23       Impact factor: 21.405

2.  Predicting Outcome in Mechanically Ventilated Pediatric Patients.

Authors:  Selman Kesici; Şenay Kenç; Ayşe Filiz Yetimakman; Benan Bayrakci
Journal:  J Pediatr Intensive Care       Date:  2019-12-03

Review 3.  Ventilatory strategies and adjunctive therapy in ARDS.

Authors:  Ajay R Desai; Akash Deep
Journal:  Indian J Pediatr       Date:  2006-08       Impact factor: 1.967

4.  Factors effecting adoption of new neonatal and pediatric respiratory technologies.

Authors:  Thomas E Bachman; Norton E Marks; Peter C Rimensberger
Journal:  Intensive Care Med       Date:  2007-10-26       Impact factor: 17.440

5.  Bias flow does not affect ventilation during high-frequency oscillatory ventilation in a pediatric animal model of acute lung injury.

Authors:  David A Turner; David F Adams; Michael A Gentile; Lee Williford; George A Quick; P Brian Smith; Ira M Cheifetz
Journal:  Pediatr Crit Care Med       Date:  2012-03       Impact factor: 3.624

6.  Early Use of Adjunctive Therapies for Pediatric Acute Respiratory Distress Syndrome: A PARDIE Study.

Authors:  Courtney M Rowan; Margaret J Klein; Deyin Doreen Hsing; Mary K Dahmer; Philip C Spinella; Guillaume Emeriaud; Amanda B Hassinger; Byron E Piñeres-Olave; Heidi R Flori; Bereketeab Haileselassie; Yolanda M Lopez-Fernandez; Ranjit S Chima; Steven L Shein; Aline B Maddux; Jon Lillie; Ledys Izquierdo; Martin C J Kneyber; Lincoln S Smith; Robinder G Khemani; Neal J Thomas; Nadir Yehya
Journal:  Am J Respir Crit Care Med       Date:  2020-06-01       Impact factor: 21.405

7.  High-Frequency Oscillatory Ventilation Use and Severe Pediatric ARDS in the Pediatric Hematopoietic Cell Transplant Recipient.

Authors:  Courtney M Rowan; Ashley Loomis; Jennifer McArthur; Lincoln S Smith; Shira J Gertz; Julie C Fitzgerald; Mara E Nitu; Elizabeth As Moser; Deyin D Hsing; Christine N Duncan; Kris M Mahadeo; Jerelyn Moffet; Mark W Hall; Emily L Pinos; Robert F Tamburro; Ira M Cheifetz
Journal:  Respir Care       Date:  2017-12-26       Impact factor: 2.258

8.  Improved oxygenation 24 hours after transition to airway pressure release ventilation or high-frequency oscillatory ventilation accurately discriminates survival in immunocompromised pediatric patients with acute respiratory distress syndrome*.

Authors:  Nadir Yehya; Alexis A Topjian; Neal J Thomas; Stuart H Friess
Journal:  Pediatr Crit Care Med       Date:  2014-05       Impact factor: 3.624

9.  Early High-Frequency Oscillatory Ventilation in Pediatric Acute Respiratory Failure. A Propensity Score Analysis.

Authors:  Scot T Bateman; Santiago Borasino; Lisa A Asaro; Ira M Cheifetz; Shelley Diane; David Wypij; Martha A Q Curley
Journal:  Am J Respir Crit Care Med       Date:  2016-03-01       Impact factor: 21.405

10.  Predictors of outcome for children requiring respiratory extra-corporeal life support: implications for inclusion and exclusion criteria.

Authors:  Nazima Pathan; Deborah A Ridout; Elizabeth Smith; Allan P Goldman; Katherine L Brown
Journal:  Intensive Care Med       Date:  2008-08-01       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.